Ultrasound and Peripheral Nerve Stimulator Guided Femoral Nerve Block

Short Term Effect of Ultrasound and Peripheral Nerve Stimulator Guided Femoral Nerve Block With Phenol on Outcomes in People With Traumatic Spinal Cord Injury

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03468439

Enrollment

Registered

2018-03-16

Start date

2014-01-31

Completion date

2016-12-31

Last updated

2018-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Keywords

nerve block

Brief summary

A pre-post descriptive study was performed to examine the immediate effects of ultrasound (US) guided femoral nerve block with phenol (UGFNBwP) in managing lower limb spasticity of individuals with traumatic spinal cord injury (SCI).

Detailed description

Study Design: A pre-post descriptive study was performed. Objectives: To examine the immediate effects of ultrasound (US) guided femoral nerve block with phenol (UGFNBwP) in managing lower limb spasticity of individuals with traumatic spinal cord injury (SCI). Setting: Ankara, Turkey Methods: Nineteen patients with traumatic SCI presenting with lower extremity spasticity were treated with UGFNBwP. Modified Ashworth Scale (MAS) of hip flexion and knee extension, functional independence measure (FIM) motor subscale, difficulty of catheterization (DoC), hygiene score (HS), spasm frequency (SF), sleep quality (SQ) and patient satisfaction (PS) were measured in all patients prior to treatment, at first week and second month.

Interventions

OTHERFemoral nerve block with phenol

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Traumatic etiology * Duration of spinal cord injury more than twelve months * Spasticity of hip flexor and/or knee extensor muscle * Use of any oral medications to reduce spasticity at stable doses for at least one month before first assessment * The patients have to accept to continue same dose until end of the last assessment * Medical clearance to participate

Exclusion criteria

* Having established contracture of the knee/hip joint * Aged over 65 years * History of surgery for knee/hip disorders * Non-traumatic etiology

Design outcomes

Primary

Measure	Time frame	Description
Modified Ashworth Scale	up to 8 weeks	Scale measures muscle tone (spasticity). (min-max:0-4).Higher values represent a worse outcome.

Secondary

Measure	Time frame	Description
Functional independence measure	up to 8 weeks	Scale measures level of independence on activities of daily life (min-max: 0-126) points).Motor subscale of FIM measure is used in this study (min-max:0-91). Higher values represent a better outcome.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026